Country/Region: Sweden
PE Guidelines

General guidelines for economic evaluations from The Dental and Pharmaceutical Benefits Agency (updated 2017)
PDF in Swedish

or clicking from https://tlv.se/verktygsmeny/om-tlv/regelverk/allmanna-rad.html

PE Guidelines Source:

The Dental and Pharmaceutical Benefits Agency (TLV)
www.tlv.se

Additional Information:

Assessment of Methods in Health Care, The Swedish Agency for Health Technology Assessment and Assessment of Social Services. August 2017.
www.sbu.se/handbook (English version, SBU’s handbook)

http://www.sbu.se/upload/ebm/metodbok/SBUsHandbok.pdf (Swedish version, SBU’s Handbook)

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)
www.sbu.se

Last Webpage Update: Friday, April 20, 2018

PE Guidelines Key Features:

Key Features:  
Title and year of the document
Ändring i Tandvårds- och läkemedelsförmånsverkets allmänna råd (TLVAR 2003:2) om ekonomiska utvärderingar (2017) 
Affiliation of authors
The Dental and Pharmaceutical Benefits Agency (TLV)  
Purpose of the document
Guidelines for the economic evaluations for submissions to TLV.  
Standard reporting format included
No 
Disclosure
Yes 
Target audience of funding/ author's interests
Pharmaceutical companies. The Dental and Pharmaceutical Benefits Agency (TLV)  
Perspective
Societal 
Indication
Yes 
Target population
Yes 
Subgroup analysis
Yes, where the treatment can be expected to differ in cost efficiency (for instance gender, age, severity, risk level)  
Choice of comparator
The most cost efficient of the available and clinically relevant treatment options in Sweden  
Time horizon
Shall cover the period when the main health effects and costs arise. 
Assumptions required
Not stated 
Preferred analytical technique
CUA, CEA, CMA  
Costs to be included
All relevant costs. Production loss estimated by human capital approach 
Source of costs
TLV.se for drugs  
Modeling
Yes, requires details 
Systematic review of evidences
Not stated 
Preference for effectiveness over efficacy
Not stated 
Preferred outcome measure
QALY. WTP in some special circumstances.  
Preferred method to derive utility
Standard gamble, time trade-off, EQ-5D. Prefer weights from ill-person. 
Equity issues stated
Not stated 
Discounting costs
Base:3%; SA:0~5%; 3% 
Discounting outcomes
Base:3%; SA:0~5%; 0% 
Sensitivity analysis-parameters and range
At central assumptions and parameters 
Sensitivity analysis-methods
Not specific 
Presenting results
Methods, assumptions made and detailed data shall be shown clearly that the different steps in the analysis are easily followed. 
Incremental analysis
Yes 
Total costs vs effectiveness (cost/effectiveness ratio)
Not specific 
Portability of results (Generalizability)
Yes, under modeling analysis 
Financial impact analysis
No 
Mandatory or recommended or voluntary
 

Acknowledgement: Sophie Werkö, PhD, MSc, Project Director, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) and Vice Chair, International Network of Agencies for Health Technology Assessment (INAHTA), Stockholm, Sweden contributed to the key feature form.

Country Selection Page | PE Guidelines Index Page